5.5 Profiling and Personalised Advertising In the context of our marketing and advertising activities, Vision Healthcare may engage in profiling within the meaning of Article 4(4) GDPR, where this is based on your prior consent
Hypoglycemia (low blood sugar) can occur, especially when Zepbound is used in combination with insulin or sulfonylureas, though the risk is lower when used as monotherapy due to its glucose-dependent mechanism of action
Safety Considerations As with any compounded sterile injectable, prescribers should screen patients before administration: G6PD deficiency: Patients with known or suspected G6PD deficiency should be evaluated carefully, as IV glutathione and related sulfhydryl compounds have been associated with hemolysis in this population
Your doctor must assess your individual medical situation, review your blood glucose patterns, and adjust dosages as needed
At a glance GLP-1 patches do not contain GLP-1 medicines like semaglutide or tirzepatide they're unregulated supplements There are no clinical trials showing these patches cause meaningful weight loss Peptide drugs are too large to pass through skin via a simple adhesive patch Popular brands like Ledisa and Kind Patches use herbal blends not prescription ingredients The MHRA has not approved any GLP-1 patch for weight loss in the UK If you're considering weight loss treatment, clinically proven options are available through regulated services What are GLP-1 patches